While the reduction in price target could be seen as a negative signal, the maintenance of an Outperform rating suggests that BMO Capital still has a positive outlook on Intellia Therapeutics' prospects. The impact on the stock price is likely to be neutral in the short term as the decrease in target is minimal and the positive rating is reaffirmed.